Regeneron Receives Another CRL for Eylea 8 mg
Regeneron faces another FDA setback for Eylea HD due to manufacturing issues.
The US Food and Drug Administration (FDA) issued a complete response letter (CRL) for the prefilled syringe option of high-dose (HD) Eylea (aflibercept) 8 mg, citing unresolved issues at the Bloomington, Indiana, plant of Novo Nordisk, Regeneron’s manufacturing partner.
- In August 2025, the FDA rejected a new blood cancer therapy due to problems at the same Novo Nordisk-owned site.
- Quality control lapses were found in November 2024, including a "pest" on the manufacturing line.
- The FDA tagged Novo's Indiana facility with an official action indicated (OAI) label.
Regeneron plans for new facilities signal future production improvements.
No specific quote available in the text.
Author's summary: Regeneron faces FDA setback for Eylea HD.
More News
- Record Job Cuts at Amazon and UPS. AI and Reorganization Changing the Face of Logistics
- ‘Mercy’ Sci-Fi Thriller Film Stars Chris Pratt and Rebecca Ferguson – Trailer and Release Date - Movie Vine
- Coats Completes Acquisition of OrthoLite | SGB Media Online
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- CNN announces election night coverage plans, including All Access-only ‘livecast’
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- Chipotle’s Stock Plunges 18% On Lowered Guidance
- VisitMalta Wins Gold At US Travel Awards For Second Year In A Row
- The Tech Symphony: AI's Crescendo and the Gadget Orchestra
- NBA head coach Tyronn Lue allegedly attended Chauncey Billups’ ‘rigged poker games’